Understanding why ovarian clear cell carcinoma resists radiation and how to make treatments more effective
Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11137606
This research explores why a specific type of ovarian cancer, called clear cell carcinoma, can be hard to treat with radiation and looks for ways to make radiation work better for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11137606 on ClinicalTrials.gov |
What this research studies
Ovarian clear cell carcinoma is a challenging cancer to treat, and this project aims to uncover the reasons behind its resistance to radiation therapy. Researchers are focusing on a gene called ARID1A, which is often mutated in this cancer, to understand how it affects the cell's ability to repair DNA damage. By understanding these molecular details, the goal is to find new ways to make radiation more powerful against these cancer cells. This could lead to more effective treatments for patients with this aggressive form of ovarian cancer.
Who could benefit from this research
Good fit: This foundational research is relevant for patients diagnosed with ovarian clear cell carcinoma, especially those whose tumors have ARID1A gene mutations.
Not a fit: Patients with other types of cancer or those without ovarian clear cell carcinoma would not directly benefit from this specific research at this stage.
Why it matters
Potential benefit: If successful, this research could lead to new drug combinations or approaches that make radiation therapy more effective for patients with ovarian clear cell carcinoma, potentially improving their outcomes.
How similar studies have performed: While the specific approach of targeting ARID1A's role in radiation resistance is novel, other studies have shown success in identifying molecular targets to improve cancer treatment responses.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PENG, GUANG — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: PENG, GUANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.